From: Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
Duration of regimen (years)
Cancer type
5
10
15
Breast
31%
53%
70%
Endometrium
18%
33%
45%
Ovary
41%
67%
84%